Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma

A Phase I Study of Immunotherapy With hA20 Administered Once Weekly for 4 Consecutive Weeks in Patients With CD20+ Non-Hodgkin's Lymphoma

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00285428

Enrollment

Registered

2006-02-02

Start date

2004-09-30

Completion date

2007-10-31

Last updated

2021-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Hodgkin's Lymphoma

Keywords

treatment, NHL, CD20+ B-cell NHL, Lymphoma

Brief summary

This is a Phase I trial to look at safety and how a patient's body will tolerate the treatment at different dosages.

Interventions

DRUGhA20-humanized anti-CD20 antibody

once weekly iv dosing for 4 weeks

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* CD20+ B-cell non-Hodgkin's lymphoma (NHL) with measurable disease

Design outcomes

Primary

Measure	Time frame
Safety and tolerance of different dose levels	12 weeks

Secondary

Measure	Time frame
Lack of immunogenicity	8 and 12 weeks
Pharmacodynamics	over 12 weeks
Pharmacokinetics	over 12 weeks
Efficacy	4, 8 and 12 wks, every 3 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026